Edgewise Therapeutics financials
$39.19−1.51%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$61.9M | -$54.1M | -$56.0M | -$46.9M | -$42.6M | -$46.0M | -$45.5M | -$40.4M | -$38.1M | -$34.8M | -$33.9M | -$29.5M |
| Net income | -$57.3M | -$49.0M | -$50.2M | -$40.7M | -$36.1M | -$40.8M | -$39.7M | -$34.1M | -$31.5M | -$28.5M | -$30.1M | -$25.7M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.53 | $-0.46 | $-0.47 | $-0.39 | $-0.34 | $-0.43 | $-0.42 | $-0.36 | $-0.34 | $-0.33 | $-0.47 | $-0.41 |
| EBITDA | -$61.4M | -$53.6M | -$55.5M | -$46.3M | -$42.1M | -$45.4M | -$45.0M | -$39.9M | -$37.7M | -$34.2M | -$33.3M | -$29.0M |
| Operating cash flow | -$42.5M | -$42.5M | -$38.6M | -$34.8M | -$32.6M | -$37.9M | -$27.0M | -$27.4M | -$26.1M | -$28.6M | -$26.8M | -$22.1M |
| Free cash flow | -$42.5M | -$42.8M | -$38.7M | -$34.9M | -$32.6M | -$37.9M | -$27.2M | -$27.9M | -$26.3M | -$28.9M | -$27.0M | -$22.5M |
| Diluted shares | 107.7M | 107.1M | 106.2M | 105.5M | 104.9M | 95.1M | 94.8M | 93.8M | 93.5M | 87.6M | 64.8M | 63.5M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $72.3M | $33.2M | $61.1M | $46.0M | $43.4M | $49.9M |
| Short-term investments | $388.4M | $466.4M | $469.0M | $517.3M | $550.6M | $386.5M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $479.7M | $518.5M | $552.6M | $583.5M | $613.3M | $454.4M |
| Total liabilities | $31.6M | $25.3M | $30.3M | $24.8M | $24.3M | $24.7M |
| Shareholders' equity | $448.1M | $493.2M | $522.3M | $558.6M | $589.1M | $429.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology